Denali Therapeutics Inc (DNLI)

$20.24 +1.01 (5.25%)
Market Cap 2.83B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,415,203
Avg Vol 1,715,276
Day's Range N/A - N/A
Shares Out 146.66M
Stochastic %K 22%
Beta 1.02
Analysts Strong Sell
Price Target $32.86

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
BullDonald
BullDonald Feb. 19 at 7:14 PM
$DNLI give me that 25 Baby, last time u missed, second time is a charm.
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 19 at 2:18 PM
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development $OTLC $DNLI $RHHBY $ALNY $WVE https://ibn.fm/sRoMP
0 · Reply
BullDonald
BullDonald Feb. 18 at 12:33 AM
$DNLI
0 · Reply
Otus
Otus Feb. 17 at 5:11 PM
$DNLI started a position here slowly over the last several months. 12 k shares. I’ll add on any significant weakness.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 14 at 3:53 PM
Our records indicate the FDA has not approved 1 new drug/therapy from non-Big Pharma year-to-date (excluding devices). Attached is a list of all the PDUFA dates YTD & the FDA response. Next 5 up to become 1st time commercial-stage bios (per our records) include $ALDX (3/16/26) $RCKT (3/28/26) $DNLI (4/5/26) $REPL (oncology 4/10/26) $GRCE (4/23/26) Our list may not be complete. This is not investment advice.
6 · Reply
onlyGreenPlz
onlyGreenPlz Feb. 13 at 11:56 PM
$DNLI Recent CRL for $IRON puts a damper on AA.
0 · Reply
BullDonald
BullDonald Feb. 13 at 9:42 PM
$DNLI THe volatility here is insane. suddenly behaving like mad stock. wash steady increase to 24 a week ago. I don see any change in fundamentals. Catalyst pending
0 · Reply
BullDonald
BullDonald Feb. 13 at 3:14 PM
$DNLI Going back to 25 soon
2 · Reply
FrostFuzz
FrostFuzz Feb. 12 at 10:09 PM
$DNLI
0 · Reply
FrostFuzz
FrostFuzz Feb. 12 at 10:03 PM
$DNLI Pre-Revenue Biotech with High Cash Burn.
1 · Reply
Latest News on DNLI
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Feb 6, 2026, 4:14 PM EST - 13 days ago

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Feb 5, 2026, 2:00 PM EST - 14 days ago

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Feb 2, 2026, 8:00 AM EST - 17 days ago

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Jan 29, 2026, 4:00 PM EST - 21 days ago

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 12:45 AM EST - 5 weeks ago

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 30, 2025, 8:00 AM EST - 7 weeks ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Dec 10, 2025, 2:47 PM EST - 2 months ago

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 10, 2025, 12:14 AM EST - 2 months ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST - 2 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Dec 5, 2025, 2:58 AM EST - 2 months ago

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 2 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Denali: Regulatory Delay Is A Strategic Opportunity

Dec 2, 2025, 8:09 AM EST - 2 months ago

Denali: Regulatory Delay Is A Strategic Opportunity

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 3:03 AM EST - 3 months ago

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 3 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Oct 14, 2025, 2:43 PM EDT - 4 months ago

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Oct 13, 2025, 4:01 PM EDT - 4 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:31 AM EDT - 5 months ago

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 6 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 6, 2025, 4:01 PM EDT - 10 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Apr 2, 2025, 8:00 AM EDT - 11 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 11 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 1 year ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Feb 6, 2025, 11:42 AM EST - 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 1 year ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 9, 2025, 3:56 PM EST - 1 year ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 6, 2025, 4:30 PM EST - 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Jan 3, 2025, 1:08 PM EST - 1 year ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 19, 2024, 10:55 PM EDT - 1 year ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 14, 2024, 2:00 PM EDT - 1 year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 6:45 AM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13, 2024, 12:30 PM EDT - 1 year ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

May 1, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 6, 2024, 10:05 PM EST - 2 years ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:05 AM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 27, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 7, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Jan 8, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 7, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

BullDonald
BullDonald Feb. 19 at 7:14 PM
$DNLI give me that 25 Baby, last time u missed, second time is a charm.
0 · Reply
NetworkNewsWire
NetworkNewsWire Feb. 19 at 2:18 PM
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development $OTLC $DNLI $RHHBY $ALNY $WVE https://ibn.fm/sRoMP
0 · Reply
BullDonald
BullDonald Feb. 18 at 12:33 AM
$DNLI
0 · Reply
Otus
Otus Feb. 17 at 5:11 PM
$DNLI started a position here slowly over the last several months. 12 k shares. I’ll add on any significant weakness.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 14 at 3:53 PM
Our records indicate the FDA has not approved 1 new drug/therapy from non-Big Pharma year-to-date (excluding devices). Attached is a list of all the PDUFA dates YTD & the FDA response. Next 5 up to become 1st time commercial-stage bios (per our records) include $ALDX (3/16/26) $RCKT (3/28/26) $DNLI (4/5/26) $REPL (oncology 4/10/26) $GRCE (4/23/26) Our list may not be complete. This is not investment advice.
6 · Reply
onlyGreenPlz
onlyGreenPlz Feb. 13 at 11:56 PM
$DNLI Recent CRL for $IRON puts a damper on AA.
0 · Reply
BullDonald
BullDonald Feb. 13 at 9:42 PM
$DNLI THe volatility here is insane. suddenly behaving like mad stock. wash steady increase to 24 a week ago. I don see any change in fundamentals. Catalyst pending
0 · Reply
BullDonald
BullDonald Feb. 13 at 3:14 PM
$DNLI Going back to 25 soon
2 · Reply
FrostFuzz
FrostFuzz Feb. 12 at 10:09 PM
$DNLI
0 · Reply
FrostFuzz
FrostFuzz Feb. 12 at 10:03 PM
$DNLI Pre-Revenue Biotech with High Cash Burn.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 4:44 PM
$DNLI RSI: 42.95, MACD: 0.4782 Vol: 1.38, MA20: 20.32, MA50: 18.66 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DoctrBenway
DoctrBenway Feb. 12 at 4:26 PM
$DNLI Just stop this tomfoolery.
0 · Reply
BullDonald
BullDonald Feb. 12 at 3:04 PM
$DNLI 1$ swing in 50K volume.... 😵‍💫
0 · Reply
Estimize
Estimize Feb. 11 at 9:00 PM
Wall St is expecting -0.75 EPS for $DNLI Q1 [Reporting 05/12 AMC] http://www.estimize.com/intro/dnli?chart=historical&metric_name=eps&utm_c
0 · Reply
DoctrBenway
DoctrBenway Feb. 11 at 8:57 PM
$DNLI sold 7% @ 19.7. Love the stock and would have loved to keep the shares, but sometimes one must raise capital.
0 · Reply
BullDonald
BullDonald Feb. 11 at 7:14 PM
$DNLI
0 · Reply
That_Millionaire_Guy
That_Millionaire_Guy Feb. 11 at 2:44 PM
$DNLI why it is taking a beating for no reason. Jess
0 · Reply
Merlintrader
Merlintrader Feb. 11 at 6:46 AM
$DNLI https://www.merlintrader.com/denali-therapeutics/
0 · Reply
dgbio
dgbio Feb. 10 at 9:17 PM
$DNLI To summarize on the Regenxbio's CRL: • They used a novel biomarker no one else is using • They failed to use a biomarker everyone else is using • The target level was set relatively high, more than 10x higher than normal, based on a very small sample of much older non-neuronopathic patients.
0 · Reply
dgbio
dgbio Feb. 10 at 8:56 PM
$DNLI One more thing on Regenxbio. They set the D2S6 target level as an upper bound of concentrations seen in attenuated (non neuronopathic) patients. This level was based on just 4 patients from Brazil aged 11 to 29. This is in a trial with patients aged 0 to 5. Why?
0 · Reply
dgbio
dgbio Feb. 10 at 3:06 PM
$DNLI Regenexbio is saying D2S6 is the most responsive to gene therapy but it's only about 20% of total. As for its association with behaviour abnormalities, it's not proven clinically. I think the problem the FDA has they take what's known to be the most responsive and use it as an endpoint and don't measure a total HS at all.
3 · Reply
dgbio
dgbio Feb. 10 at 1:56 PM
$DNLI Denali unlike Regenxbio uses total HS as a biomarker and not just D2S6. Ultragenyx uses total HS as well for UX111 in MPS IIIA. Ultargenyx got a CRL on manufacturing issues but no problems with using total HS as a biomarker were mentioned.
1 · Reply